Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephen Benz

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
NPJ Genomic Medicine|June 22, 2018
Identification of an immune gene expression signature associated with favorable clinical features in Treg-enriched patient tumor samplesKevin B Givechian, Kamil Wnuk, Chad Garner, et al.
In Silico Biology|October 28, 2004
A DNA Motif Lexicon: cataloguing and annotating sequencesBetsey D Dyer, Mark D LeBlanc, Stephen Benz, et al.
Breast Cancer Research and Treatment|October 13, 2015
FOXM1 cistrome predicts breast cancer metastatic outcome better than FOXM1 expression levels or tumor proliferation indexChristina Yau, Laurence Meyer, Stephen Benz, et al.
Nature Methods|April 1, 2009
The UCSC Cancer Genomics BrowserJingchun Zhu, J Zachary Sanborn, Stephen Benz, et al.
Cancer Research|September 5, 2006
Breast cancer growth prevention by statinsMichael J Campbell, Laura J Esserman, Yamei Zhou, et al.
Frontiers in Oncology|December 29, 2022
Case report: Complete pathologic response with first-line immunotherapy combination in a young adult with massive liver dissemination of mismatch repair-deficient metastatic colorectal cancer: Immunological and molecular profilingFrancesca Bergamo, Silvia Dalla Santa, Fotios Loupakis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 4, 2023
Inferred Immune-Cell Activity Is an Independent Predictor of HER2-Negative Breast Cancer Prognosis and Response to Paclitaxel-Based Therapy in the GeparSepto TrialPeter A Fasching, Christopher Szeto, Carsten Denkert, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 31, 2014
Targeting RPL39 and MLF2 reduces tumor initiation and metastasis in breast cancer by inhibiting nitric oxide synthase signalingBhuvanesh Dave, Sergio Granados-Principal, Rui Zhu, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
NPJ Genomic Medicine|June 22, 2018
Identification of an immune gene expression signature associated with favorable clinical features in Treg-enriched patient tumor samplesKevin B Givechian, Kamil Wnuk, Chad Garner, et al.
In Silico Biology|October 28, 2004
A DNA Motif Lexicon: cataloguing and annotating sequencesBetsey D Dyer, Mark D LeBlanc, Stephen Benz, et al.
Breast Cancer Research and Treatment|October 13, 2015
FOXM1 cistrome predicts breast cancer metastatic outcome better than FOXM1 expression levels or tumor proliferation indexChristina Yau, Laurence Meyer, Stephen Benz, et al.
Nature Methods|April 1, 2009
The UCSC Cancer Genomics BrowserJingchun Zhu, J Zachary Sanborn, Stephen Benz, et al.
Cancer Research|September 5, 2006
Breast cancer growth prevention by statinsMichael J Campbell, Laura J Esserman, Yamei Zhou, et al.
Frontiers in Oncology|December 29, 2022
Case report: Complete pathologic response with first-line immunotherapy combination in a young adult with massive liver dissemination of mismatch repair-deficient metastatic colorectal cancer: Immunological and molecular profilingFrancesca Bergamo, Silvia Dalla Santa, Fotios Loupakis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 4, 2023
Inferred Immune-Cell Activity Is an Independent Predictor of HER2-Negative Breast Cancer Prognosis and Response to Paclitaxel-Based Therapy in the GeparSepto TrialPeter A Fasching, Christopher Szeto, Carsten Denkert, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 31, 2014
Targeting RPL39 and MLF2 reduces tumor initiation and metastasis in breast cancer by inhibiting nitric oxide synthase signalingBhuvanesh Dave, Sergio Granados-Principal, Rui Zhu, et al.
Pageof 1